NCT00013689View on ClinicalTrials.gov

Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2001

Study Completion Date

March 31, 2003

Conditions
Autoimmune DiseaseLymphoproliferative Disorder
Interventions
DRUG

Fansidar (pyrimethamine and sulfadoxine)

Trial Locations (1)

20892

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00013689 - Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome | Biotech Hunter | Biotech Hunter